Greenberg Traurig is extremely proud to represent Redhill Biopharma with the recent announcement of providing an initial update on the compassionate use program with its investigational drug, opaganib, in patients
Continue Reading Greenberg Traurig Is Proud to Represent Redhill Biopharma Treating COVID-19 Patient with Opaganib in Israel Under Compassionate Use

Coronavirus Disease 2019 (COVID-19) is causing unprecedented disruptions to the U.S. economy. Government officials and health professionals are predicting that these disruptions could continue through September. Businesses are having to
Continue Reading Risk Allocation for Economic Losses from Coronavirus Disease 2019

While it is too early to predict how long the Coronavirus Disease 2019 (COVID-19) will disrupt everyday life, it isn’t too soon to proactively consider your potential risk and understand
Continue Reading Coronavirus Disease 2019 and Force Majeure Contract Clauses

U.S. life sciences companies with ties overseas can be encouraged by a recent federal ruling that denied the request of foreign companies to conduct discovery in the United States in
Continue Reading Federal Court Denies Request of Foreign Companies to Conduct Discovery in the United States in Aid of a Foreign-Seated Arbitration